Granular ox bile extract with a compacted particle size distribution is transferred from double polyethylene-lined drums into a calibrated cone mill fitted with a 0.5 mm round-hole screen; oversize aggregates retained above 0.8 mm are returned to the mill until the entire batch passes the screen. Direct-compression blends containing 150–300 mg of ox bile extract per unit are prepared by pre-blending the milled API with colloidal silicon dioxide at 0.5% w/w and microcrystalline cellulose for 10 minutes in a 600 L V-blender at 25 rpm. Croscarmellose sodium is then added and mixed for an additional 8 minutes. Magnesium stearate 0.25–0.5% w/w is introduced last and mixed for only 2 minutes at 15 rpm, because prolonged lubrication reduces tablet tensile strength and increases disintegration variability in direct-compression formulations of this API. The final blend is compressed on an instrumented rotary press with 10.5 mm round flat-faced bevel-edge tooling. Compression force is adjusted to achieve crush strength between 49 N and 98 N; friability assessed by USP <1216> is maintained below 1.0% to avoid edge chipping during film coating. Disintegration is measured in purified water at 37±2°C per USP <701>; the acceptance criterion is linked to the finished product monograph and is commonly not more than 30 minutes for uncoated tablets. Dissolution testing per USP <711> is conducted in 900 mL phosphate buffer pH 6.8 with 0.5% w/v polysorbate 80 to maintain sink conditions, because bile salts form micelles that can otherwise suppress free dissolution and produce high foam volume in the vessel.

How does moisture ingress during high-speed capsule filling alter fill weight stability?

Ox bile extract is hygroscopic; incoming bulk powder with loss on drying exceeding 5.0% w/w as measured by infrared moisture balance at 105°C is associated with adhesion to dosator pins and non-uniform slug formation on intermittent-motion capsule machines. The powder is dried in a vacuum tray dryer at 45°C under 25 mbar until loss on drying falls below 3.0% w/w. Hard HPMC capsules are selected preferentially over gelatin because the low equilibrium moisture of HPMC shell reduces brittle fracture at relative humidity below 40% and prevents shell softening at relative humidity above 60%. On a dosator-type capsule filler, fill weight repeatability is monitored at 15-minute intervals using a checkweigher; acceptance is set at not more than 3.0% relative standard deviation for a 250 mg fill. Dosator pin height is adjusted so that the compressed powder bed height remains between 5.0 mm and 7.0 mm; increasing powder bed height beyond 8.0 mm causes over-compaction and delayed disintegration. The filled capsules are placed in HDPE bottles with silica gel desiccant canisters; headspace relative humidity is held below 25% during storage. Disintegration of the filled capsules is assessed by USP <701> with a wire spiral; because bile extract can promote foam in the disintegration medium, the addition of polysorbate 80 is permitted only if specified in the finished product monograph. Published data for specific fill-weight drift at production speeds above 100,000 capsules/hour using crude ox bile extract is limited, so parameter ranges are established on the qualified machine.

Granulation and enteric coating of sachet-strength ox bile extract granules

Water-based wet granulation of ox bile extract is avoided because the API forms a sticky mass in the presence of aqueous binders at granulation temperatures above 35°C. Dry granulation by roller compaction is performed on a vertical roller compactor with ribbed rolls; the compacted ribbon is milled through a 0.8 mm screen. Granules with a targeted size fraction between 0.25 mm and 0.85 mm are collected; fines below 0.25 mm are recycled at a rate not exceeding 15% of total batch weight to avoid excessive dust and segregation. The granules are coated in a bottom-spray fluid bed with methacrylic acid–ethyl acrylate copolymer dispersion, triethyl citrate plasticizer at 10–15% of dry polymer solids, and talc anti-tack. Coating weight gain between 8% and 10% is required to obtain acid resistance; acid-stage dissolution in 900 mL 0.1 M hydrochloric acid for 2 hours shows not more than 10% release, followed by buffer-stage release in 900 mL phosphate buffer pH 6.8. The delayed-release profile is checked by USP <711> with a basket speed of 100 rpm and sinker. Sachet filling is conducted on a vertical form-fill-seal machine at 25°C and relative humidity below 35%; each sachet contains 1.0 g or 2.0 g of enteric-coated granules. In-process fill weight tolerance is ±5.0% per sachet. Because bile extract granules are susceptible to electrostatic charging, an ionising bar is positioned at the sachet forming tube to reduce weight variation caused by granule cling.

Oral liquid forms of ox bile extract present simultaneous challenges of bitter taste, foam generation, and photolytic discolouration. Reconstitution from granules at the point of dispensing is preferred over multi-dose aqueous liquids because the API degrades in aqueous solution faster than in dry granule form. When reconstitution is specified, purified water at 40°C is added to a target volume of 50 mL; water hardness above 120 mg/L calcium carbonate equivalents is avoided because divalent cations can interact with bile salt micelles and produce turbidity. Polysorbate 80 at 0.1% w/v may be added under mixing at 300 rpm for 5 minutes; the solution is then dosed immediately. Foam generation during mixing is controlled with simethicone emulsion at 0.2% v/v, and the vessel is filled to a pre-calibrated mark to avoid headspace-dependent foam rise. The reconstituted liquid is stored in amber glass bottles protected from light; bile pigments in ox bile extract are light-sensitive and darkening occurs when exposed to ultraviolet light at 365 nm for more than 24 hours. Chemical stability is assessed by total bile salt assay; a drop of more than 5.0% from initial assay is considered out-of-trend. The dose is administered through an oral syringe and should be consumed within 30 minutes, because microbial proliferation in a non-preserved reconstituted liquid exceeds 10 CFU/mL at ambient temperature after 2 hours. If preservative is required for multi-dose packaging, potassium sorbate 0.1% w/v and sodium benzoate 0.1% w/v are added before pH adjustment to 5.5.

When injectable-grade ox bile extract is specified, particulate-control and haemolysis testing must define the process boundary

Crude ox bile extract intended for parenteral administration differs fundamentally from oral-grade material. Animal-derived API must be accompanied by viral safety documentation and TSE/BSE country-of-origin certification; purification steps are typically validated for removal of proteinaceous impurities and bile pigments using activated carbon treatment followed by membrane filtration. Injectable solutions are prepared in a Grade A laminar airflow with Grade B background per EU GMP Annex 1; the product is passed through a 0.22 μm PVDF membrane filter. Because bile salts are surface-active and can form visible particulates upon pH adjustment, pH is controlled at 7.0–7.4 with phosphate buffer. Bacterial endotoxin is measured by USP <85>; the limit is derived from the maximum bolus dose using the formula K/M, where K is set at 5 EU/kg for intravenous non-intrathecal products. The resulting product-specific endotoxin limit for the API is therefore dose-dependent, not a fixed value. Particulate matter is evaluated by USP <788> light obscuration particle count; limits for small-volume injections are not more than 6000 particles per container for ≥10 μm and not more than 600 particles per container for ≥25 μm. In vitro haemolysis testing is mandatory because bile salts can lyse erythrocytes at concentrations above their critical micellar concentration. Samples incubated with rabbit or human erythrocytes at 37°C for 60 minutes must show not more than 2.0% haemolysis at the proposed clinical concentration. If terminal steam sterilisation at 121°C for 15 minutes is evaluated, degradation products and colour change must be monitored against the unsterilised control. Published data for specific injectable formulations using crude ox bile extract are limited; product development therefore requires additional preclinical safety qualification.

Fixed-dose digestive enzyme combinations require separated granule fractions before final blending

Ox bile extract is co-formulated with pancreatin or pepsin in solid oral dosage forms for digestive enzyme replacement and choleretic indications. Because bile salts are amphiphilic and can reduce enzyme activity in wet mass, the enzyme component and bile extract component are granulated separately. Pancreatin is dry-blended with lactose monohydrate and cellulose, compacted, and milled to a particle size fraction of 0.25 mm to 0.71 mm; the bile extract component is dry-granulated as described above. The two granule fractions are combined in a low-shear tumble blender at 15 rpm for 20 minutes. Segregation risk is minimised by matching bulk density within 0.10 g/mL and by filling capsules or tablets immediately after blending. Enzyme activity is assayed by USP pancreatin monograph methods; lipase activity is determined by tributyrin titration, amylase by starch substrate, and protease by casein digestion. Stability studies under ICH Q1A conditions at 40°C and 75% RH are used to establish whether the bile extract causes activity loss; when lipase activity drops more than 10% from initial, the enzyme fraction is protected with an enteric coating before blending. Tablets are compressed with a low compression force to avoid enzyme denaturation; capsule filling is performed at room temperature below 25°C because pancreatic enzymes degrade rapidly above 30°C. The final product must meet USP <905> uniformity of dosage units; the acceptance value is not more than 15.0.